NEW YORK, August 21, 2026, 18:00 EDT
- Shares of Picard Medical finished at $3.21, with trading volume reaching 4.47 million shares.
- Trading volume on Friday was 54 times higher than on Thursday, but the stock still posted an 8.8% weekly decline.
- The second-quarter loss of $5.7 million amounted to roughly 86% of Friday’s market value of $6.59 million.
Shares in Picard Medical, Inc. NYSEAMERICAN:PMI saw trading volume reach 4.47 million on Friday, marking a 54-fold surge compared to Thursday. The stock finished up 5.9% at $3.21, yet was still down 8.8% from its closing price on Monday.
The rapid rise challenges investors to weigh strong operational gains against significant financing concerns. Picard’s quarterly loss of $5.7 million came close to its market capitalization at close, which stood at $6.59 million. The contrast is stark: the loss for a single quarter was about 86% of Picard’s total equity value.
| Date | Close | Daily move | Volume |
|---|---|---|---|
| Aug. 17 | $3.52 | down 0.3% | 49,130 |
| Aug. 18 | $3.24 | down 8.0% | 60,030 |
| Aug. 19 | $3.29 | up 1.5% | 69,330 |
| Aug. 20 | $3.03 | down 7.9% | 82,360 |
| Aug. 21 | $3.21 | up 5.9% | 4,468,000 |
Despite the market swings, underlying performance improved. Revenue for the second quarter advanced 39% to roughly $3.0 million. Gross margin improved to 20.9%, recovering from a negative margin of 6.0% in the same period last year. Most of the revenue growth came from sales in the United States.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.0 million | $2.1 million | up 39% |
| Gross profit | $0.6 million | -$0.1 million | Profit returned |
| Gross margin | 20.9% | -6.0% | gain of 26.9 points |
| Net loss | $5.7 million | $6.7 million | Loss reduced by 16% |
The six-month results were more complex. Revenue rose 50% to $4.1 million, but the net loss also grew, reaching $13.3 million compared with $12.3 million. The figures highlight that improving margins by itself does not resolve the valuation issue.
Interim Chief Executive Richard Fang said, “We are encouraged by the progress reflected in our second-quarter results,” while also noting “the work that remains ahead of us.” The company added it is still assessing further financing options. Company statement
Liquidity is key to that warning. Picard held only $121,000 in cash as of March 31, a decline from $7.45 million at the previous year-end. Operating cash outflows totaled $3.8 million in the first quarter. The company’s filing expressed significant uncertainty over its ability to remain a going concern.
The capital structure has been modified. Picard executed a one-for-50 reverse stock split on July 31. Trading on a split-adjusted basis started August 3. NYSE American approved a compliance plan; however, the company is still required to satisfy ongoing listing requirements.
| Analyst | Latest action | Rating | Published target | Investor read-through |
|---|---|---|---|---|
| Stifel | Reiterated, July 1 | Buy | $195 | The target is impacted by a significant post-split gap and isn’t reliable without updated validation |
| H.C. Wainwright | Reaffirmed, June 4 | Hold | Not listed | Maintains a neutral view |
| Tracked consensus | Last three months | Neutral | Not meaningful | Current snapshot: 0 Buy, 1 Hold, 0 Sell |
Analyst coverage provides limited backing for the company’s valuation. At present, just a single Hold rating is noted in the summary. Stifel’s target price of $195 is posted, but that figure stands well above Friday’s close. The target’s proximity to the reverse split highlights a noteworthy data-quality alert.
SynCardia Systems is owned by Picard. The company’s total artificial heart is approved for commercial use in both the United States and Canada. Picard reports that over 2,100 implants have taken place in 27 countries. Investors are backing this established clinical record.
The stock changed hands at $4.81 in after-hours trading as of 17:35:05 EDT, up 49.9% post-close. There was no new company filing released alongside this quote. Limited liquidity following the closing bell often leads to sharper fluctuations in micro-cap share prices.
Investors are set to monitor if Friday’s trading volume continues next week. Attention will also be on updates about financing, progress towards exchange compliance, and indications that positive gross margin holds up amid increased sales. These factors carry more significance than any single volatile day.
Risks: Issuing new equity may significantly dilute current shareholders. A failed listing, limited liquidity or reduced implant demand could weigh on the stock. On the other hand, improved financing conditions or continued margin improvements could lift the valuation.
Related articles: Earnings
![Australia Stock Market Today 08.22.2026 [UPDATE: 08.22.2026 08:37 AEST] [Weekly Recap and Week Ahead: Healthcare Leads, CPI Looms]](https://ts2.tech/wp-content/uploads/2026/08/AU-market-dashboard-2026-08-22-0837-480x384.jpg "Australia Stock Market Today 08.22.2026 [UPDATE: 08.22.2026 08:37 AEST] [Weekly Recap and Week Ahead: Healthcare Leads, CPI Looms]")
